Related Experiment Video
Updated: Aug 9, 2026
09:29
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Alcoholism and neuropeptides: an update
1Howard Florey Institute and Centre for Neuroscience, University of Melbourne, VIC 3010, Australia. m.cowen@hfi.unimelb.edu.au
CNS & Neurological Disorders Drug Targets
|April 14, 2006
Summary
Developing new alcoholism treatments is crucial. Targeting neuropeptide systems offers promising therapeutic strategies to prevent relapse and manage alcohol withdrawal symptoms effectively.
Area of Science:
- Neuroscience and Pharmacology
- Addiction Research
- Molecular Psychiatry
Background:
- Alcoholism is a chronic relapsing condition requiring effective long-term therapeutic strategies.
- Current treatments aim to prevent relapse and manage withdrawal, but improved options are needed.
- Neuropeptide systems are increasingly recognized for their role in addiction and alcohol-seeking behaviors.
Purpose of the Study:
- To explore the therapeutic potential of targeting neuropeptide systems for alcoholism treatment.
- To identify specific neuropeptide receptors as viable targets for novel anti-alcoholism drugs.
- To review existing and potential pharmacological interventions for alcohol use disorder.
Main Methods:
- Review of pre-clinical and clinical data on neuropeptide systems in alcoholism.
- Analysis of the efficacy of opioid receptor antagonists (e.g., naltrexone) in managing alcohol dependence.
- Identification of other neuropeptide targets, including corticotrophin-releasing factor (CRF), neuropeptide Y, and nociceptin receptors.
Main Results:
- Non-selective opioid receptor antagonists represent an established therapeutic strategy for alcoholism.
- Pre-clinical evidence suggests neuropeptide systems are implicated in alcohol-seeking behavior.
- Corticotropin-releasing factor (CRF), neuropeptide Y, and nociceptin receptors show potential as therapeutic targets.
Conclusions:
- Neuropeptide systems offer promising avenues for developing novel, effective alcoholism therapeutics.
- Targeting specific neuropeptide receptors could help regulate alcohol consumption and mitigate withdrawal.
- Further research into these targets may lead to improved clinical strategies for preventing relapse in alcohol addiction.
More Related Videos
05:12Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
07:50A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
Related Concept Videos
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:17Drug Dependence
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...